Welcome to our dedicated page for Lantheus Holding SEC filings (Ticker: LNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lantheus Holdings, Inc. filings document its radiopharmaceutical operating results, Nasdaq-listed common stock, governance and material corporate events. Form 8-K reports furnish quarterly and annual financial results, business updates, FDA-related disclosures for diagnostic and therapeutic radiopharmaceutical products, share repurchase authorization, and executive and board changes.
Proxy materials describe director elections, executive compensation, shareholder voting matters and equity incentive plan approvals. The filings also cover material modifications to security holder rights, Regulation FD disclosures and capital-structure details relevant to common stock issued by a public radiopharmaceutical company.
Lantheus Holdings, Inc. reported that its Chief Commercial Officer, Amanda Morgan, has informed the company that she is taking leave from the company for personal reasons, effective August 8, 2025. The filing does not indicate any change to her title or name a replacement in this excerpt, only that she will be on leave. The update is presented as a leadership availability change rather than a broader strategic or financial event.
Lantheus (LNTH) Q2-25 10-Q highlights:
- Revenue slipped 4% YoY to $378.0 M as PYLARIFY sales moderated (-8%) and TechneLite continued to decline ahead of the planned SPECT divestiture. Six-month revenue down 2% to $750.8 M.
- Gross margin held at 64% (241.0/378.0). Opex flat YoY; R&D down 25% as AZEDRA spend ended. Operating income fell 14% to $88.0 M, but lower unrealised equity losses and higher interest income lifted net income 27% to $78.8 M (dil. EPS $1.12).
- Six-month net income dropped 22% to $151.7 M as Q1 faced a sharp mark-to-market equity loss.
- Cash flow from ops was a solid $194.7 M, offset by $296.2 M investing cash outflow, chiefly the $269 M acquisition of radiotherapeutics CDMO Evergreen Theragnostics. Cash & equivalents fell to $695.6 M; net cash still ~>$120 M versus $575 M 2.625% converts.
- Balance sheet adds $116.2 M Evergreen goodwill and $215 M IPR&D; fair-valued contingent consideration booked at $43.0 M.
- SPECT business classified as held-for-sale (assets $73.4 M, liabilities $29.8 M) under agreement with SHINE; no impairment recorded.
- Shareholder returns: repurchased 1.3 M shares for $100 M in Q2; $200 M total under $250 M 2024 program. 68.0 M basic shares outstanding (-2% YoY).
- Leverage covenants remain comfortable (net leverage 0.6×); no borrowings under $750 M revolver.
Outlook: While topline softness persists near term, the Evergreen acquisition broadens manufacturing capacity and adds Octevy & CDMO revenue options; SPECT sale will further concentrate on high-growth PET oncology and diagnostics franchise.
Lantheus (LNTH) Q2-25 10-Q highlights:
- Revenue slipped 4% YoY to $378.0 M as PYLARIFY sales moderated (-8%) and TechneLite continued to decline ahead of the planned SPECT divestiture. Six-month revenue down 2% to $750.8 M.
- Gross margin held at 64% (241.0/378.0). Opex flat YoY; R&D down 25% as AZEDRA spend ended. Operating income fell 14% to $88.0 M, but lower unrealised equity losses and higher interest income lifted net income 27% to $78.8 M (dil. EPS $1.12).
- Six-month net income dropped 22% to $151.7 M as Q1 faced a sharp mark-to-market equity loss.
- Cash flow from ops was a solid $194.7 M, offset by $296.2 M investing cash outflow, chiefly the $269 M acquisition of radiotherapeutics CDMO Evergreen Theragnostics. Cash & equivalents fell to $695.6 M; net cash still ~>$120 M versus $575 M 2.625% converts.
- Balance sheet adds $116.2 M Evergreen goodwill and $215 M IPR&D; fair-valued contingent consideration booked at $43.0 M.
- SPECT business classified as held-for-sale (assets $73.4 M, liabilities $29.8 M) under agreement with SHINE; no impairment recorded.
- Shareholder returns: repurchased 1.3 M shares for $100 M in Q2; $200 M total under $250 M 2024 program. 68.0 M basic shares outstanding (-2% YoY).
- Leverage covenants remain comfortable (net leverage 0.6×); no borrowings under $750 M revolver.
Outlook: While topline softness persists near term, the Evergreen acquisition broadens manufacturing capacity and adds Octevy & CDMO revenue options; SPECT sale will further concentrate on high-growth PET oncology and diagnostics franchise.
Lantheus Holdings (LNTH) Form 8-K highlights: On 21-Jul-25 the company’s UK subsidiary closed the previously announced acquisition of Life Molecular Imaging Ltd. for an upfront cash payment of $350 million, securing 100 % of the target’s share capital in line with the January 2025 Sale & Purchase Agreement.
Item 7.01 discloses that a 22-Jul-25 press release (Exhibit 99.1) announced the closing and the appointment of Dr. Ludger Dinkelborg as Head of Research & Development, effective 1-Aug-25. He will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management and AI/Biomarkers Solutions, reporting to the CEO.
No financial statements or pro-forma figures accompany the filing; the report focuses solely on completion of the asset acquisition and the senior leadership change.